LGALS1 and Parkinson disease: Our validation experiment for Gal-1 confirmed our findings from the discovery study, indicating that mass spectrometry profiling of proteins in CSF may be a useful tool to indentify novel biomarkers of neurological diseases, but this validation also demonstrated that CSF Gal-1 levels were similar in PD and APD.